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A B S T R A C T
Introduction: Hypoparathyroidism is a rare complication of iron overload in patients with transfusion dependent
β thalassemia major (β-TM). We aim to determine the prevalence of parathyroid dysfunction in patients with β-
TM.
Methods: Diagnosed cases of transfusion dependent β-TM between 5 and 17 years of age were recruited from
outpatient clinics of a non-profit organization in Karachi, Pakistan. Blood and urine samples were collected in
fasting to determine Ca, P, Alb, Mg, Cr 25OHD and iPTH. Patients were grouped on the basis of upper and lower
levels of Ca, 25OHD and iPTH for assessing parathyroid dysfunction into primary hypoparathyroidism [low
calcium (Ca) & intact parathyroid hormone (iPTH)], sub-clinical hypoparathyroidism [low iPTH and 25 hydroxy
vitamin D (25OHD), low/normal Ca], normal functioning parathyroid gland [Normal Ca, iPTH and 25OHD] and
secondary hyperparathyroidism [high iPTH, low/normal Ca and/or 25OHD]. Using PTH nomogram subject spe-
cific expected PTH (maxPTH) was calculated. Difference between maxPTH and measured iPTH was determined
to assess the utility of nomogram in identifying parathyroid gland dysfunction. The statistical analysis was
performed using the Statistical Package of Social Sciences (SPSS) version 20.
Results: Median age of patients was 11 years (13–7) with males being 54.2% (n=205).
Based on Ca, 25OHD and iPTH, primary hypoparathyroidism was identified in 3.4% (n= 13) [median iPTH
11.3 pg/ml (12.6–7)], 52.3% (n=192) had subclinical hypoparathyroidism [iPTH 40.4 pg/ml (52.7–28.7)], and
34% (n= 125) were identified as secondary hyperparathyroidism [iPTH 88.6 pg/ml (116–74.7)]. Normal re-
sponse to Ca & 25OHD was seen in 10.6% (n=39) [iPTH 44.2 pg/ml (53.8–33.4)] patients. High phosphorous
was present in all groups. Difference between maxPTH & iPTH was highest in primary hypoparathyroidism,
followed by subclinical and secondary hyperparathyroidism.
Conclusion: Nomogram by Harvey et al. identify low secretion capacity of parathyroid gland that correlated with
biochemical classification of patients. It requires clinical validation before using in clinical practice for assessing
parathyroid dysfunction.
1. Introduction
Parathyroid dysfunction notably hypoparathyroidism, is a rare
complication of iron overload in patients with transfusion dependent β
thalassemia major (β-TM) [1,2]. Manifestations of hypoparathyroidism
include tetany, seizures, carpopedal spasms, and paresthesia, which
may or may not be accompanied by hypocalcemia [3]. It is re-
commended to screen for parathyroid dysfunction periodically, when
other iron overload associated complications occur, as ferritin levels do
not provide a reliable index of parathyroid function [4].
The availability of different treatment modalities has increased
quality and life expectancy of patients with thalassemia worldwide [5].
However, in Pakistan due to inadequate management; treatment related
complications continue to add to morbidity in these patients.
In a cross sectional survey of patients with transfusion dependent β-
TM, our group reported iron over load and delayed physical growth [6].
In addition, in the same group of patients altered bone and mineral
homeostasis (as indicated by hypocalcemia, hyperphosphatemia, vi-
tamin D deficiency and altered parathyroid hormone activity) was
identified with high frequency of pain and fractures in 12.5% of
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patients (submitted for publication). Both high and low levels of intact
Parathyroid hormone levels (iPTH) were noted. However, the inter-
pretation of the iPTH levels to assess both primary and secondary hyper
and hypo functioning of the gland can only be made in association with
calcium (Ca) and phosphorus (P).
With recently identified newer phenotypes of hyperparathyroidism
including normocalcemic hyperparathyroidism (NCHPT), hy-
percalcemia with inappropriately normal iPTH and functional hypo-
parathyroidism (subjects who do not demonstrate secondary hy-
perparathyroidism (SHPT) despite vitamin D deficiency); interpretation
has become more challenging. Isolated levels of biochemical parameter
do not provide an indication of the existing functional abnormality in
the parathyroid gland in patients [7]. Identification of parathyroid
gland dysfunction poses a major challenge for physicians engage in
managing patients with β-TM.
Harvey et al. used mathematical modeling to develop a multi-
dimensional nomogram to provide a biologically sensitive estimation of
PTH taking serum Ca and 25 hydroxy vitamin D (25OHD) that phy-
siologically regulate PTH release. Comparison of estimated PTH
(maxPTH) from the nomogram with actually measured plasma iPTH
level can assist a clinician in differentiating different parathyroid dis-
eases. This is especially helpful in differentiating newer phenotypes,
especially when they do not conform to an easy diagnostic category [8].
The aim of this study was to determine the prevalence of different
types of parathyroid dysfunction in transfusion dependent β-TM using
biochemical markers and assess the difference between measured and
maxPTH using nomogram by Harvey et al. for its application in clinical
practice. The anthropometric measurements and bone and mineral
abnormalities have been described previously in these patients [6].
2. Methods
2.1. Study setting, patient recruitment and data collection
Study setting and patient recruitment has been described previously
[6]. Briefly, 367 diagnosed cases of transfusion dependent β-TM be-
tween 5 and 17 years of age were recruited from the outpatient clinics
of a non-profit organization providing free of cost blood components to
the patients with various chronic blood disorder. Study was approved
by ethical review committee of Aga Khan University Hospital. Blood
samples were collected in fasting to analyze the following parameters:
vitamin D (25OHD), calcium (Ca), intact parathyroid hormone (iPTH),
phosphorus (P), magnesium (Mg), zinc (Zn), creatinine (Cr), albumin
(Alb), SGPT, urinary Ca and Cr.
2.2. Classification of subjects into clinical groups
Subjects were categorized into clinical groups based on corrected
calcium, iPTH and 25OHD as follows:
1. Primary hypoparathyroidism: patients with clinical and biochemical
evidence of hypoparathyroidism including low Ca and iPTH below
the reference interval irrespective of 25OHD status (Ca<8.6mg/dl,
iPTH<15 pg/ml).
2. Sub-clinical hypoparathyroidism: includes patients with low iPTH
and 25OHD, low and normal Ca levels (Ca ≤8.6–10.2, iPTH
15–65 pg/ml, 25OHD<20 ng/ml).
3. Patients with normal functioning parathyroid gland: Normal Ca and
iPTH and optimal 25OHD (Ca 8.6–10.2, iPTH 15–65 pg/ml,
25OHD>20 ng/ml).
4. Secondary hyperparathyroidism: include patients with high iPTH
with either Ca and/or 25OHD deficiency (Ca<8.6mg/dl and/or
25OHD<20mg/dl, iPTH>65 pg/ml
2.3. Application of PTH nomogram to calculate difference between
maxPTH and measured PTH to identify hypoparathyroidism
We calculated patient specific upper limit of normal PTH (maxPTH)
using equation developed by Harvey et al. [120 - (6 × calcium) - (0.5
× 25OHD) + (0.25 × age)], in our patients [8]. This equation cal-
culates the expected PTH for a specific subject on the basis of total Ca,
25OHD, and age measured on the same day.
Subject specific maxPTH was used to calculate the difference from
measured PTH (iPTH) to identify patients with hypoparathyroidism/
parathyroid gland dysfunction in each group. Taking allowable error of
plasma PTH as 33.43%, difference between maxPTH & iPTH greater
than allowable error was calculated. This work has been reported in
line with the STROCSS criteria [9].
2.4. Data analysis
The statistical analysis was performed using the Statistical Package
of Social Sciences (SPSS) version 20. Data distribution was assessed by
Shapiro-Wilk test for normality. Frequency was generated for catego-
rical and medians with interquartile range (IQR) for continuous vari-
ables. Mann-Whitney U Test was performed to assess association of
biochemical parameters amongst different clinical groups.
Table 1
Biochemical parameters of bone health in children with transfusion dependent β-thalassemia major (n=367).
Biochemical Parameters Median (Q3-Q1) Hyper/Hypo Functioning States Frequency (%) Median (IQR)
Intact-PTH (pg/ml) 52.7 (75.6–33.5) Low < 15 16 (4.4) 11.4 (12.68–7.4)
Normal 15–65 224 (61) 41.2 (52.9–30.5)
High > 65 127 (34.6) 88.6 (116–74.6)
Vitamin D (ng/ml) 13.09 (18.7–8.56) Deficient < 20 287 (78.2) 11.05 (14.5–7.67)
Sufficient > 20 80 (21.8) 25.59 (29.6–21.97)
Corrected Calcium (mg/dl) 8.8 (9.4–7.96) Low < 8.6 155 (42.2) 7.86 (8.21–7.09)
Normal 8.6–10.2 212 (57.8) 9.3 (9.62–9)
Serum Phosphate (mg/dl) 5.1 (5.9–4.3) Low 17 (4.6) 2.46 (2.68–2.37)
Normal 216 (58.8) 4.69 (5–4.16)
High 134 (36.5) 6.13 (7–5.7)
Serum Magnesium (mg/dl) 2.01 (2.18–1.84) Low 52 (14.2) 1.51 (1.63–1.31)
Normal 205 (55.9) 1.96 (2–1.87)
High 110 (29.97) 2.3 (2.44–2.2)
Fractional Excretion of Calcium (FeCa) % 0.2 (0.5–0.1) Normal < 1 334 (91) 0.2 (0.4–0.1)
High > 1 31 (8.4) 1.3 (2.1–1.2)
Results are presented as median (Q3-Q1), and frequency (percentages).
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3. Results
3.1. Biochemical parameters of bone health in patients with transfusion
dependent β-TM
Table 1 reflects, overall and hypo/hyper function and deficient/
sufficient states as measured by low and high values for all analytes in
367 patients with transfusion dependent β-TM. Majority of the patients
had vitamin D deficiency (78.2%), with only 21.9% having sufficient
vitamin D levels.
3.2. Biochemical classification of patients
Table 2 shows the distribution of 367 patients, grouped into dif-
ferent groups based on their median Ca, 25OHD and iPTH blood levels
with the median (IQR) levels of individual analytes in each clinical
group.
Majority (51%) of the patients had sub-clinical hypoparathyroidism
followed by secondary hyperparathyroidism (34%). Among the 16 pa-
tients with low iPTH levels (Table 1), 05 were normocalcemic with
median 25OHD levels of 12.5 ng/ml, suggestive of hypoparathyroidism.
Median Mg levels were within range, while high median P was
present in all groups with highest level in patients grouped as primary
hypoparathyroidism followed by subclinical hypoparathyroidism and
secondary hyperparathyroidism group. Of note, is the high median P in
the group despite normal response of parathyroid gland.
Median 25OHD levels were deficient in all other groups, but despite
a similar vitamin D deficient state the response of the gland shows
progressive worsening of parathyroid glandular function with advan-
cing age and ferritin levels as is reflected by iPTH, in Table 2 in dif-
ferent groups.
Limited number (10.6%, n= 39) with normal response of iPTH
were identified to have normal levels of corrected Ca, Mg, iPTH, and
25OHD levels, but P levels were high in 7 of these patients.
3.3. Application of PTH nomogram by Harvey et al
Patient specific max PTH was calculated using age, Ca and 25OHD
status using nomogram developed by Harvey et al. Table 3 compares
the median iPTH measured in the laboratory with the median expected
PTH (maxPTH) calculated by the nomogram. The table also shows the
number of individuals with difference in calculated ‘maxPTH’ and
measured ‘iPTH’ was greater than the allowable error for PTH in dif-
ferent groups.
Difference between maxPTH & iPTH was highest in primary hypo-
parathyroidism, followed by subclinical and secondary hyperparathyr-
oidism. High values are predicted by nomogram for all three groups.
The median expected PTH in clinical group of secondary hy-
perparathyroidism at a given age, calcium and 25OHD is lower than the
measured iPTH. Non-significant differences were observed in iPTH and
maxPTH in the normally functioning gland.
4. Discussion
In this study, we identified 11 undiagnosed patients of hypopar-
athyroidism at median age of 13 years indicating need for earlier
screening. The reason for this is inadequate chelation as is indicated by
high ferritin. Most of thalassemia guidelines are from developed
countries, where strict measures are taken to ensure adequate chela-
tion, so they recommend screening for hypoparathyroidism from 16
years. In our data we observed that primary hypoparathyroidism de-
veloped from the age of 12 years (median 13 years), while average age
of patients with subclinical hypoparathyroidism was 11 years. Most
guidelines on thalassemia managment recommend screening for hy-
poparathyroidism at 16 years by assessing Ca & P; followed by PTH if
low Ca or P is found. We propose that in developing countries screeningTa
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for parathyroid dysfunction should start from 9 years onwards.
This is the first study, where we have use a unique classification for
categorization of parathyroid disorders in a high risk population where
the main cause of parathyroid gland deregulation is iron deposition.
The varying biochemical manifestations require interpretation specific
for each case. Simultaneous laboratory testing with relevant markers
including Ca, P, iPTH and 25OHD is important for diagnosis, clinical
correlation and interpretation especially in areas where vitamin D de-
ficiency is endemic. Patients can easily be missed if the analytes are
tested individually. We have previously reported usefulness of the si-
multaneous testing of markers using bone health screening panel in
detecting newer phenotypes of primary hyperparathyroidism and va-
lidating by applying nomogram by Harvey et al. [7]. Further, in this
study we have determined its utility in calculating expected parathyroid
hormone levels to determine hypo functioning. We found obvious dif-
ferences in the secretary capacity of parathyroid gland in the four
groups for expected PTH.
Using upper and lower cut-offs of biomarkers we describe a phase
that can be regarded as sub-clinical hypoparathyroidism or impending
hypoparathyroidism where there is inappropriately normal PTH levels
in response to either vitamin D deficiency or low Ca levels. This re-
quires repeat testing to confirm for primary hypoparathyroidism as well
as follow-up for monitoring. We also identified 5 cases in which Ca
levels were normal with low PTH levels and vitamin D deficiency. A
probable explanation could be intravenous infusion of calcium which is
very frequently given to these patients when they present with tingling
and/or twitching based on presumption that hypocalcemia is a cause
without testing for calcium or PTH.
It is believed that parathyroid glands have large reserves. A biphasic
chronological time course is described for hyperparathyroidism; in the
first sub-clinical phase PTH levels are elevated but serum Ca is normal,
and this phase remains sub-clinical because PTH levels are rarely
measured with normal serum calcium concentration [10]. Third Inter-
national Workshop on the Management of Asymptomatic Primary Hy-
perparathyroidism officially recognized and labeled this phase as Nor-
mocalcemic hyperparathyroidism in 2008 [11]. This phase is followed
by the development of frank hypercalcemia and a symptomatic disorder
with bone loss and kidney stones. Whether, the same time course exist
for hypoparathyroidism, has not been established till to date. Cusano
et al. reported prevalence of 1.1–1.9% normocalcemic hypoparathyr-
oidism (NHYPO) in two unselected, non-referral community dwelling
population from MrO and DHS [12]. NHYPO is not yet considered a real
diagnostic category as data is not available. Sixty eight subjects were
identified by Cusano with statistically significant differences in bone
turnover markers (bone alkaline phosphatase and cTX) than in normal
group. However, none developed overt hypoparathyroidism on follow-
up and persistent disease was noted in only 2 out of 26 subjects.
Calcium phosphate product was>55 in 15%, increase in fractional
excretion of calcium was also noted in 8.4% of patients, which is
alarming and requires careful supplementation tailored to specific need
of each patient, shown in Table 4. Unmonitored treatment with either
Ca or vitamin D may end in altered calcium phosphate product and the
risk of tumor calcinosis and nephrocalcinosis in patients [13]. More-
over, if hypoparathyroidism evolves than it is important to provide
replacement with 1 alpha vitamin D in addition to cholecalciferol [14].
Abnormal levels for Ca, P and Mg (Table 1) are prevalent in this study.
However, we did not find any association of Mg levels with PTH levels.
The primary end point of our study is to identify the prevalence of
parathyroid hormone disorders in a high risk group of patients. The
manifestations of abnormalities in patients with thalassemia patients is
alarming and calls for the need for optimization of thalassemia man-
agement [15]. Our findings clearly highlights the need for using si-
multaneous measurement of markers for assessment of parathyroid
activity. In addition, application of nomogram has shown beneficial
results in our previous (7) and this study. This requires clinical vali-
dation for confirmation.
This is the first study in Pakistan that has addressed parathyroid
gland dysfunction in thalassemia major and highlighted the importance
of improper chelation leading to morbidity in this children. Findings are
alarming and requires immediate attention for optimization of man-
agement. There is a strong need to determine our population specific
guidelines for diagnosis and management of bone related problems.
Over the past decades, management of patients with thalassemia has
improved significantly. However, thalassemia major remains a common
and serious hematological problem in Pakistan. There is dire need to
address bone health issues in these patients in Pakistan.
Table 3
Median Expected PTH (maxPTH) and Difference in maxPTH & iPTH in Different Groups of Parathyroid Dysfunction (n= 367).
Parathyroid Gland Status n iPTH pg/ml maxPTH pg/ml maxPTH & iPTH difference pg/ml Difference≥Allowable Error
Primary Hypoparathyroidism 11 11.3 (12.6–7) 79.5 (87.3–67.1) 72.3 (76.5–54.5) 11 (100)
Subclinical Hypoparathyroidism 192 40.4 (52.7–28.7) 66.4 (73–60.9) 27.6 (42.1–12.3) 134 (69.8)
Normal Response for PTH 39 44.2 (53.8–33.4) 51.2 (53.5–49.2) −5.2 (18 to −4.8) 13 (33.3)
Secondary Hyperparathyroidism 125 88.6 (116–74.7) 57.6 (65.2–57.6) 26.3 (−13.4 to −55.7) 53 (42.4)
P value – < 0.001 <0.001 <0.001 –
Results are presented as median (Q3-Q1) and frequency (%). The maxPTH was calculated using Harvey et al. PTH nomogram [120 - (6 × calcium) -
(0.5 × 25OHD) + (0.25 × age)]. Allowable error of plasma parathyroid hormone was 33.43% [reference: Westgard database of Desirable Specifications for Total
Error (derived from Imprecision, Bias, intra- and inter-individual biologic variation) https://www.westgard.com/biodatabase1.htm. Accessed on 12/4/18].
Table 4
Distribution of calcium phosphate product and fractional excretion of calcium in different groups.
Parathyroid Gland Status n Urinary FeCa Serum Calcium×Serum Phosphate Product
Median (Q3-Q1) frequency of > 1% Median (Q3-Q1) > 55
Primary Hypoparathyroidism 11 0.37 (0.75–0.09) 1 53.3 (62–44.4) 5
Subclinical Hypoparathyroidism 192 0.003 (0.006–0.001) 19 42.9 (51.2–35.1) 31
Normal Response for iPTH 39 0.27 (0.75–0.11) 5 45.5 (51.1–36.9) 8
Secondary Hyperparathyroidism 125 0.21 (0.44–0.09) 6 47.3 (53–41.2) 11
P value – 0.06 < 0.001
Results are presented as Median (Q3-Q1) and Frequency. Where FeCa stands for fractional excretion of calcium calculated by [(urinary calcium/serum cal-
cium)× (serum creatinine/urinary creatinine)× 100].
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